Phase I/II and Pharmacokinetic Study of Intravenous Vinflunine in Combination With Cisplatin for the Treatment of Chemonaive Patients With Advanced Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

Phase I/II and Pharmacokinetic Study of Intravenous Vinflunine in Combination With Cisplatin for the Treatment of Chemonaive Patients With Advanced Non–Small-Cell Lung Cancer

Published:2010-03 Issue:2 Volume:11 Page:105-113
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Souquet Pierre-Jean,Krzakowski Maciej,Ramlau Rodrig,Sun Xu-Shan,Lopez-Vivanco Guillermo,Puozzo Christian,Pouget Jean Christophe,Pinel Marie Claire,Rosell Rafael

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference36 articles.

1. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised trials;Non small Cell Lung Cancer Cooperative Group;BMJ,1995

2. Chemotherapy for advanced non-small cell lung cancer;Dubey;Hematol Oncol Clin N Am,2004

3. Vinca alkaloids in superacidic media: a method for creating a new family of antitumor derivatives;Fahy;J Am Chem Soc,1997

4. Novel actions of the antitumour drugs vinflunine and vinorelbine on microtubules;Ngan;Cancer Res,2000

5. Antimiotic and tubulin-interacting properties of vinflunine, a novel fluorinated vinca alkaloid;Kruczynski;Biochem Pharmacol,1998

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse drug reactions of anticancer drugs derived from natural sources;Food and Chemical Toxicology;2019-01

2. New insights into Vinca alkaloids resistance mechanism and circumvention in lung cancer;Biomedicine & Pharmacotherapy;2017-12

3. Anti-mitotic agents: Are they emerging molecules for cancer treatment?;Pharmacology & Therapeutics;2017-05

4. Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience;Therapeutic Advances in Urology;2016-11-21

5. Vinflunine for the treatment of non-small cell lung cancer;Expert Opinion on Investigational Drugs;2016-11